LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

LLY

986

-0.26%↓

JNJ

224.47

-0.51%↓

ABBV

204.99

-0.5%↓

UNH

366.96

+0.87%↑

AZN

184.44

+1.73%↑

Home・Aktien・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Geschlossen

BrancheGesundheitswesen

32.72 2.89

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

31.8

Max

32.79

Schlüsselkennzahlen
By Trading Economics
Einkommen	-28M 22M
Verkäufe	4.3M 244M
KGV Branchendurchschnitt	11.723 49.8
Gewinnspanne	9.224
Angestellte	293
EBITDA	-22M 52M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+31.6% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	338M 1.9B
Vorheriger Eröffnungskurs	29.83
Vorheriger Schlusskurs	32.72

Nachrichtenstimmung

By Acuity

100%

331 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

29.8 / N/A Unterstützung & Widerstand

Harmony Biosciences Holdings Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

6. Mai 2026, 23:41 UTC

Ergebnisse

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6. Mai 2026, 21:40 UTC

Ergebnisse

Nutrien Logs Higher Profit, Sales Growth in 1Q

6. Mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6. Mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6. Mai 2026, 23:13 UTC

Ergebnisse

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6. Mai 2026, 23:12 UTC

Ergebnisse

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6. Mai 2026, 23:11 UTC

Ergebnisse

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6. Mai 2026, 23:07 UTC

Ergebnisse

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6. Mai 2026, 23:06 UTC

Ergebnisse

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6. Mai 2026, 23:05 UTC

Ergebnisse

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6. Mai 2026, 23:04 UTC

Ergebnisse

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6. Mai 2026, 22:50 UTC

Ergebnisse

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6. Mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6. Mai 2026, 22:11 UTC

Ergebnisse

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6. Mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6. Mai 2026, 21:58 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:47 UTC

Market Talk

Ergebnisse

Costco Posts 13% Sales Growth in April -- Market Talk

6. Mai 2026, 21:46 UTC

Ergebnisse

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6. Mai 2026, 21:40 UTC

Ergebnisse

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6. Mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6. Mai 2026, 21:32 UTC

Heiße Aktien

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6. Mai 2026, 21:29 UTC

Ergebnisse

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Peer-Vergleich

Kursveränderung

Harmony Biosciences Holdings Inc Prognose

Kursziel

By TipRanks

31.6% Vorteil

12-Monats-Prognose

Durchschnitt 42.89 USD 31.6%

Hoch 72 USD

Tief 25 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Harmony Biosciences Holdings Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

Buy

Halten

Sell

Basierend auf 9 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Harmony Biosciences Holdings Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

29.8 / N/AUnterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Stimmung

By Acuity

331 / 347 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.